TY  - JOUR
AU  - Goldschmidt, Hartmut
AU  - Lokhorst, H. M.
AU  - Mai, E. K.
AU  - van der Holt, B.
AU  - Blau, I. W.
AU  - Zweegman, S.
AU  - Weisel, K. C.
AU  - Vellenga, E.
AU  - Pfreundschuh, M.
AU  - Kersten, M. J.
AU  - Scheid, C.
AU  - Croockewit, S.
AU  - Raymakers, R.
AU  - Hose, D.
AU  - Potamianou, A.
AU  - Jauch, A.
AU  - Hillengass, J.
AU  - Stevens-Kroef, M.
AU  - Raab, M. S.
AU  - Broijl, A.
AU  - Lindemann, H. W.
AU  - Bos, G. M. J.
AU  - Brossart, P.
AU  - van Marwijk Kooy, M.
AU  - Ypma, P.
AU  - Duehrsen, U.
AU  - Schaafsma, R. M.
AU  - Bertsch, U.
AU  - Hielscher, Thomas
AU  - Jarari, Le
AU  - Salwender, H. J.
AU  - Sonneveld, P.
TI  - Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
JO  - Leukemia
VL  - 32
IS  - 2
SN  - 1476-5551
CY  - Basingstoke
PB  - Nature Publ. Group
M1  - DKFZ-2018-00163
SP  - 383 - 390
PY  - 2018
AB  - The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95
LB  - PUB:(DE-HGF)16
C6  - pmid:28761118
DO  - DOI:10.1038/leu.2017.211
UR  - https://inrepo02.dkfz.de/record/132475
ER  -